BDSX Jul 2024 2.500 call
| Previous close | 0.3000 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.0500 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 53 |
Business WireBiodesix to Participate in the 2024 RBCCM Global Healthcare Conference
LOUISVILLE, Colo., May 07, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the 2024 RBCCM Global Healthcare Conference, which will be held from May 14-15, 2024.
Business WireBiodesix to Report First Quarter 2024 Financial Results on May 8, 2024
LOUISVILLE, Colo., April 24, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Simply Wall St.The recent US$4.0m market cap decrease is likely to have disappointed insiders invested in Biodesix, Inc. (NASDAQ:BDSX)
Key Insights Significant insider control over Biodesix implies vested interests in company growth 53% of the business...
